Norepinephrine Kabi (Noradrenaline Tartrate)

Norepinephrine binds directly to alpha‑1 adrenergic receptors on vascular smooth muscle, causing strong vasoconstriction that increases systemic vascular resistance and arterial pressure. It also stimulates beta‑1 receptors in the heart, modestly enhancing heart rate and contractility, which together support cardiac output in shock states.

The dosing regimen for Norepinephrine Kabi is individualized. A prescriber determines the initial infusion rate and subsequent titration based on the patient’s hemodynamic response, target mean arterial pressure, and clinical condition. Continuous monitoring guides adjustments to achieve therapeutic goals while minimizing adverse effects.

Safety data for norepinephrine during pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Use is generally reserved for situations where the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be administered only under specialist supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Both norepinephrine and dopamine are catecholamine vasopressors, but norepinephrine has a stronger alpha‑1 effect, producing more reliable vasoconstriction with less tachycardia. Dopamine also stimulates dopaminergic receptors, which can cause renal vasodilation at low doses. Clinicians often prefer norepinephrine for septic shock because of its predictable hemodynamic profile.

Norepinephrine Kabi must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

The product is given by continuous intravenous infusion, typically through a central venous catheter to reduce the risk of extravasation. The infusion is started at a low rate and titrated based on real‑time blood pressure measurements, aiming for the target mean arterial pressure set by the treating physician.

Serious adverse events include severe hypertension, myocardial ischemia, life‑threatening arrhythmias, tissue necrosis from extravasation, and pulmonary edema. Continuous hemodynamic monitoring and prompt recognition of these signs are essential to adjust therapy and prevent irreversible organ damage.

Norepinephrine Kabi is contraindicated in patients with known hypersensitivity to norepinephrine or any excipients in the formulation. Caution is advised in individuals with severe peripheral vascular disease, uncontrolled hypertension, or those at high risk for myocardial ischemia, where the vasoconstrictive effects may exacerbate underlying conditions.